Clinical trial
SP01A: The Study of an Oral Entry Inhibitor in Treatment-Experienced HIV…
NCT00299897 · Samaritan Pharmaceuticals, Inc, Industry · Unknown status
Key facts
| NCT number | NCT00299897 |
|---|---|
| Title | SP01A: The Study of an Oral Entry Inhibitor in Treatment-Experienced HIV Patients |
| Official title | A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Orally Administered SP01A for 28 Days as Monotherapy Treatment in HIV-Infected Patients With Evidence of Resistance to Currently Available Antiretroviral Therapy |
| Lead sponsor | Samaritan Pharmaceuticals, Inc, Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections, Human Immunodeficiency Virus |
| Intervention type | Drug |
| Interventions | SP01A |
| Enrollment | 60 |
| Start date | Mar 1, 2006 |
| First posted | Mar 7, 2006 |
| Last update posted | Oct 27, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: